CONRAD and the South African Government’s Technology Innovation Agency (TIA) on Tuesday announced a license agreement that grants TIA the rights to manufacture and distribute tenofovir gel in Africa, according to a CONRAD statement.  TIA also will establish a joint venture with drug maker Cipla Medpro and iThemba Pharmaceuticals for the registration, manufacturing and distribution of the gel in South Africa and other African nations (6/14). A large trial of tenofovir gel among women was also announced on Tuesday (6/15).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.